| Patient | Rachel Carson |
|---|---|
| Date of birth | 1973-05-27 |
| Identifiers | MRN HR-ML041-SYN; SSN (made up) 000-41-5068 |
| Document date | 2026-11-01 |
| Author | Margaret Vance-Okonkwo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Primary care visit for a new left breast lump; follow-up of a recently treated duodenal ulcer. Concerns: A firm lump in the left breast she found two weeks ago; Wants to be told plainly and in person what any test shows, to see the reports herself, and to make her own decisions; asks that her health be shared only with the people she chooses; Worried that illness will keep her from finishing her book. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Omeprazole 20 mg delayed-release oral capsule, one capsule by mouth once daily before breakfast, to complete eight weeks of ulcer healing | One capsule once daily before breakfast | Oral route | 2026-01-19 to 2026-04-03 | completed | S |
| Acetaminophen 500 mg oral tablet, two tablets (1000 mg) by mouth up to three times a day as needed for knee pain, no more than 3000 mg a day | Two tablets up to every 8 hours as needed | Oral route | 2025-06-02 | active | S |
| Letrozole 2.5 mg oral tablet, one tablet by mouth once daily, planned for at least five years | One tablet once daily | Oral route | 2026-06-15 | active | S |
| Ribociclib 200 mg oral tablet, two tablets (400 mg) by mouth once daily on days 1 to 21 of each 28-day cycle, with letrozole, planned for three years | Two tablets once daily on days 1 to 21 of each 28-day cycle | Oral route | 2026-06-15 | active | S |
| Zoledronic acid 4 mg in 100 mL intravenous infusion over 15 minutes every six months for three years | One infusion every six months | Intravenous route | 2026-06-15 | active | S |
| Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily | One tablet once daily | Oral route | 2026-06-15 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Diagnostic mammography of the left breast with a right breast view: 2.4 cm irregular spiculated mass at 2 o'clock in the upper outer left breast; scattered fibroglandular density; right breast normal; BI-RADS 5 | 2026-03-11 to 2026-03-11 | completed | S |
| Left breast and axillary ultrasound: 2.4 cm irregular hypoechoic mass at 2 o'clock, 7 cm from the nipple; axillary lymph nodes normal in size and shape | 2026-03-11 to 2026-03-11 | completed | S |
| Ultrasound-guided core needle biopsy of the left breast mass with clip placement: invasive ductal carcinoma, grade 2; ER 95 percent, PR 80 percent, HER2 1+ (negative), Ki-67 22 percent | 2026-03-13 to 2026-03-13 | completed | S |
| Genetic counseling and germline multigene panel testing for inherited breast cancer risk: no pathogenic variant | 2026-03-18 to 2026-03-18 | completed | S |
| Left breast lumpectomy (breast-conserving surgery) with wire-free localization of the biopsy clip, her informed choice. Pathology: invasive ductal carcinoma 2.3 cm, grade 2, margins clear (closest 4 mm), no lymphovascular invasion; pT2. Recurrence score (21-gene assay) 17 | 2026-04-06 to 2026-04-06 | completed | S |
| Left axillary sentinel lymph node biopsy at lumpectomy: 2 of 3 nodes with macrometastases (largest 6 mm), no extranodal extension; pN1a(sn) | 2026-04-06 to 2026-04-06 | completed | S |
| 13C urea breath test four weeks after bismuth quadruple therapy and two weeks after stopping omeprazole: negative; Helicobacter pylori eradicated | 2026-04-17 to 2026-04-17 | completed | S |
| Hypofractionated radiation to the left whole breast and regional lymph nodes, 40 Gy in 15 fractions, with a tumor-bed boost of 10 Gy in 4 fractions; completed with grade 1 skin reddening | 2026-05-04 to 2026-05-29 | completed | S |
| Baseline bone density scan (DXA) before letrozole: lumbar spine T-score -1.8, femoral neck T-score -1.3 (low bone mass) | 2026-06-15 to 2026-06-15 | completed | S |
| Baseline 12-lead electrocardiogram before ribociclib: sinus rhythm 70/min, QTcF 418 ms | 2026-06-15 to 2026-06-15 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2025-10-14 | Influenza vaccine, 2025-2026 season | completed | S |
| 2021-05-10 | Tdap vaccine | completed | S |
| 2026-10-13 | Influenza vaccine, 2026-2027 season | completed | S |
| 2026-10-13 | Pneumococcal conjugate vaccine PCV20 | completed | S |
| 2026-10-13 | Recombinant zoster vaccine, dose 1 of 2 | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1950 | Benign tumor removed from the left breast | D (CLM-0004) |
| Early 1960 | Two lumps found in the left breast while writing a book | D (CLM-0006) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| A firm lump in the left breast she found two weeks ago | active | S |
| Wants to be told plainly and in person what any test shows, to see the reports herself, and to make her own decisions; asks that her health be shared only with the people she chooses | active | S |
| Worried that illness will keep her from finishing her book | active | S |
Most recent measures: Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-10-13; Hemoglobin [Mass/volume] in Blood 12.2 on 2026-07-20; Leukocytes [#/volume] in Blood by Automated count 2.9 on 2026-07-20; Platelets [#/volume] in Blood by Automated count 168 on 2026-07-20; Creatinine [Mass/volume] in Serum or Plasma 0.8 on 2026-09-08; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 31 on 2026-09-08; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 29 on 2026-09-08; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 2026-09-08; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 5 on 2026-04-20; Neutrophils [#/volume] in Blood by Automated count 1.2 on 2026-07-20; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 87 on 2026-06-15; Bilirubin.total [Mass/volume] in Serum or Plasma 0.7 on 2026-09-08; Potassium [Moles/volume] in Serum or Plasma 4.1 on 2026-09-08; Magnesium [Mass/volume] in Serum or Plasma 2 on 2026-09-08; Calcium [Mass/volume] in Serum or Plasma 9.5 on 2026-09-08; Cholesterol [Mass/volume] in Serum or Plasma 208 on 2026-06-15; Cholesterol in HDL [Mass/volume] in Serum or Plasma 62 on 2026-06-15; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 124 on 2026-06-15; Triglyceride [Mass/volume] in Serum or Plasma 110 on 2026-06-15; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 34 on 2026-09-08; Q-T interval corrected 418 on 2026-06-15; DXA Lumbar spine [T-score] Bone density -1.8 on 2026-06-15; DXA Femur [T-score] Bone density -1.3 on 2026-06-15; Total score [AUDIT-C] 1 on 2026-10-13 [S]
Strengths and supports: Supports: a close friend and her editor; she shares health news with very few people [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Invasive ductal carcinoma of the left breast, upper outer quadrant at 2 o'clock, 2.4 cm on imaging; core biopsy grade 2, estrogen and progesterone receptor positive, HER2 negative, Ki-67 22 percent; clinical stage T2 N0 (cT2 cN0 M0); synthetic modern counterpart of the documented 1960 breast cancer, which was not disclosed to her | active | confirmed | C50.412 | S — Synthetic tumor details, stage, and treatment; the breast lumps, the 1960 operation, and the nondisclosure are documented (D), but no tumor details from her lifetime are used. |
| Estrogen receptor positive status of the breast cancer (ER 95 percent, PR 80 percent) | active | confirmed | Z17.0 | S — Synthetic receptor result; no receptor status from her lifetime is known. |
| New firm lump in the upper outer quadrant of the left breast, found two weeks ago; clinically suspicious; diagnostic imaging and biopsy booked | resolved | confirmed | N63.21 | S — Synthetic presenting concern at the index visit, superseded by the biopsy diagnosis; the lumps in the left breast in early 1960 are documented (D). |
| Duodenal ulcer found at endoscopy seven weeks ago, with Helicobacter pylori on biopsy; treated with 14 days of bismuth quadruple therapy and completing eight weeks of omeprazole; test of cure planned | resolved | confirmed | K26.9 | S — Synthetic modern ulcer; it echoes the ulcer among her documented illnesses, which the sources do not date. |
| Primary osteoarthritis of both knees, mild, with stiffness after long walks on the shore | active | confirmed | M17.0 | S — Synthetic condition; it is not linked to the documented word arthritis, which she may have used to keep her cancer private. |
| Metastatic carcinoma in two of three left axillary sentinel lymph nodes (macrometastases, no extranodal extension); pathologic stage pT2 pN1a(sn) M0, anatomic stage IIB; recurrence score 17 | active | confirmed | C77.3 | S — Synthetic surgical pathology; spread to lymph nodes is documented later in her life, but no pathology from her lifetime is used. |
| Long-term use of letrozole as adjuvant endocrine therapy, with ribociclib for three years | active | confirmed | Z79.811 | S — Synthetic treatment status. |
| Low bone mass (osteopenia) on baseline DXA before letrozole: lumbar spine T-score -1.8, femoral neck -1.3; 10-year major osteoporotic fracture risk about 7 percent (FRAX); vitamin D insufficiency | active | confirmed | M85.80 | S — Synthetic finding on the baseline DXA the protocol requires for an aromatase inhibitor. |
| Acute viral rhinosinusitis for five days while on ribociclib, with expected grade 2 neutropenia (absolute neutrophil count 1.2) and no fever; resolved with saline irrigation | resolved | confirmed | J01.90 | S — Synthetic common illness; it echoes the sinus infection among her documented illnesses, which the sources do not date, and is not linked to that claim. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-03-09 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 2026-03-09 | Hemoglobin [Mass/volume] in Blood | 12.3 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-03-09 | Leukocytes [#/volume] in Blood by Automated count | 6.4 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-03-09 | Platelets [#/volume] in Blood by Automated count | 262 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-03-09 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.5-1.1 mg/dL | Normal | S |
| 2026-03-09 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 18 | U/L | <=33 U/L | Normal | S |
| 2026-03-09 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 20 | U/L | <=32 U/L | Normal | S |
| 2026-03-18 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 2026-03-18 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 8 | {score} | S | ||
| 2026-04-20 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 2026-04-20 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 5 | {score} | S | ||
| 2026-06-15 | Hemoglobin [Mass/volume] in Blood | 12.8 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-06-15 | Leukocytes [#/volume] in Blood by Automated count | 5.9 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-06-15 | Neutrophils [#/volume] in Blood by Automated count | 3.4 | 10*3/uL | 1.8-7.7 10*3/uL | Normal | S |
| 2026-06-15 | Platelets [#/volume] in Blood by Automated count | 240 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-06-15 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.5-1.1 mg/dL | Normal | S |
| 2026-06-15 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 87 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-06-15 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 20 | U/L | <=33 U/L | Normal | S |
| 2026-06-15 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | <=32 U/L | Normal | S |
| 2026-06-15 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | <=1.2 mg/dL | Normal | S |
| 2026-06-15 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-06-15 | Magnesium [Mass/volume] in Serum or Plasma | 2.1 | mg/dL | 1.7-2.4 mg/dL | Normal | S |
| 2026-06-15 | Calcium [Mass/volume] in Serum or Plasma | 9.4 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-06-15 | Cholesterol [Mass/volume] in Serum or Plasma | 208 | mg/dL | <=199 mg/dL | High | S |
| 2026-06-15 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 62 | mg/dL | >=50 mg/dL | Normal | S |
| 2026-06-15 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 124 | mg/dL | <=99 mg/dL | High | S |
| 2026-06-15 | Triglyceride [Mass/volume] in Serum or Plasma | 110 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-06-15 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 22 | ng/mL | 30-100 ng/mL | Low | S |
| 2026-06-15 | Q-T interval corrected | 418 | ms | Ribociclib is started only when QTcF is below 450 ms | Normal | S |
| 2026-06-15 | DXA Lumbar spine [T-score] Bone density | -1.8 | {T-score} | >=-1 | Low | S |
| 2026-06-15 | DXA Femur [T-score] Bone density | -1.3 | {T-score} | >=-1 | Low | S |
| 2026-09-08 | Hemoglobin [Mass/volume] in Blood | 12.5 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-09-08 | Leukocytes [#/volume] in Blood by Automated count | 3.4 | 10*3/uL | 4-11 10*3/uL | Low | S |
| 2026-09-08 | Neutrophils [#/volume] in Blood by Automated count | 1.6 | 10*3/uL | 1.8-7.7 10*3/uL | Low | S |
| 2026-09-08 | Platelets [#/volume] in Blood by Automated count | 192 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-09-08 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.5-1.1 mg/dL | Normal | S |
| 2026-09-08 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 31 | U/L | <=33 U/L | Normal | S |
| 2026-09-08 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 29 | U/L | <=32 U/L | Normal | S |
| 2026-09-08 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.7 | mg/dL | <=1.2 mg/dL | Normal | S |
| 2026-09-08 | Potassium [Moles/volume] in Serum or Plasma | 4.1 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-09-08 | Magnesium [Mass/volume] in Serum or Plasma | 2 | mg/dL | 1.7-2.4 mg/dL | Normal | S |
| 2026-09-08 | Calcium [Mass/volume] in Serum or Plasma | 9.5 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-09-08 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 34 | ng/mL | 30-100 ng/mL | Normal | S |
| 2026-09-08 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 2026-07-20 | Leukocytes [#/volume] in Blood by Automated count | 2.9 | 10*3/uL | 4-11 10*3/uL | Low | S |
| 2026-07-20 | Neutrophils [#/volume] in Blood by Automated count | 1.2 | 10*3/uL | 1.8-7.7 10*3/uL | Low | S |
| 2026-07-20 | Hemoglobin [Mass/volume] in Blood | 12.2 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-07-20 | Platelets [#/volume] in Blood by Automated count | 168 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-10-13 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-10-13 | Total score [AUDIT-C] | 1 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-09 | Body height | 163 | cm | S |
| 2026-03-09 | Body weight | 59.4 | kg | S |
| 2026-03-09 | Body mass index (BMI) [Ratio] | 22.4 | kg/m2 | S |
| 2026-03-09 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-03-09 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-03-09 | Heart rate | 76 | /min | S |
| 2026-03-09 | Respiratory rate | 14 | /min | S |
| 2026-03-09 | Body temperature | 36.7 | Cel | S |
| 2026-03-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-03-18 | Body height | 163 | cm | S |
| 2026-03-18 | Body weight | 59 | kg | S |
| 2026-03-18 | Body mass index (BMI) [Ratio] | 22.2 | kg/m2 | S |
| 2026-03-18 | Systolic blood pressure | 130 | mm[Hg] | S |
| 2026-03-18 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-03-18 | Heart rate | 84 | /min | S |
| 2026-03-18 | Respiratory rate | 16 | /min | S |
| 2026-03-18 | Body temperature | 36.6 | Cel | S |
| 2026-03-18 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-04-20 | Body height | 163 | cm | S |
| 2026-04-20 | Body weight | 58.6 | kg | S |
| 2026-04-20 | Body mass index (BMI) [Ratio] | 22.1 | kg/m2 | S |
| 2026-04-20 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-04-20 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-04-20 | Heart rate | 74 | /min | S |
| 2026-04-20 | Respiratory rate | 14 | /min | S |
| 2026-04-20 | Body temperature | 36.7 | Cel | S |
| 2026-04-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-06-15 | Body height | 163 | cm | S |
| 2026-06-15 | Body weight | 58.9 | kg | S |
| 2026-06-15 | Body mass index (BMI) [Ratio] | 22.2 | kg/m2 | S |
| 2026-06-15 | Systolic blood pressure | 120 | mm[Hg] | S |
| 2026-06-15 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-06-15 | Heart rate | 70 | /min | S |
| 2026-06-15 | Respiratory rate | 14 | /min | S |
| 2026-06-15 | Body temperature | 36.6 | Cel | S |
| 2026-06-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-09-08 | Body height | 163 | cm | S |
| 2026-09-08 | Body weight | 59.6 | kg | S |
| 2026-09-08 | Body mass index (BMI) [Ratio] | 22.4 | kg/m2 | S |
| 2026-09-08 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-09-08 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-09-08 | Heart rate | 72 | /min | S |
| 2026-09-08 | Respiratory rate | 14 | /min | S |
| 2026-09-08 | Body temperature | 36.6 | Cel | S |
| 2026-09-08 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-07-20 | Body height | 163 | cm | S |
| 2026-07-20 | Body weight | 59.2 | kg | S |
| 2026-07-20 | Body mass index (BMI) [Ratio] | 22.3 | kg/m2 | S |
| 2026-07-20 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-07-20 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-07-20 | Heart rate | 82 | /min | S |
| 2026-07-20 | Respiratory rate | 16 | /min | S |
| 2026-07-20 | Body temperature | 37.3 | Cel | S |
| 2026-07-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-10-13 | Body height | 163 | cm | S |
| 2026-10-13 | Body weight | 59.8 | kg | S |
| 2026-10-13 | Body mass index (BMI) [Ratio] | 22.5 | kg/m2 | S |
| 2026-10-13 | Systolic blood pressure | 116 | mm[Hg] | S |
| 2026-10-13 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-10-13 | Heart rate | 70 | /min | S |
| 2026-10-13 | Respiratory rate | 14 | /min | S |
| 2026-10-13 | Body temperature | 36.6 | Cel | S |
| 2026-10-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-03-09 | Primary care visit for a new left breast lump; follow-up of a recently treated duodenal ulcer | finished | S |
| 2026-03-18 | Disclosure of the biopsy diagnosis of breast cancer and shared decision-making, with the breast surgical oncology consultation the same day | finished | S |
| 2026-04-20 | Review two weeks after lumpectomy and sentinel node biopsy: full disclosure of the pathology and the adjuvant treatment decision | finished | S |
| 2026-06-15 | Start of letrozole, ribociclib, and zoledronic acid after radiation | finished | S |
| 2026-09-08 | Monitoring visit at the start of the fourth ribociclib cycle | finished | S |
| 2026-07-20 | Same-day sick visit for sinus symptoms on ribociclib | finished | S |
| 2026-10-13 | Adult preventive visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Diagnostic mammography and ultrasound of the left breast and axilla this week, then image-guided core biopsy with ER, PR, HER2, and Ki-67 testing | completed | GL-NCCN-BREAST-2025, GL-CMID-2026 | S |
| Breast surgical oncology consultation once the biopsy result is available, to discuss surgical options and axillary staging with her | completed | GL-NCCN-BREAST-2025 | S |
| Disclosure and shared decision-making: ask what she wants to know, give each result in person and in plain words with a written copy, check understanding by teach-back, and make every decision with her; share her health information only with the people she names | completed | GL-AMA-2.1.3, GL-ASCO-COMM-2017 | S |
| Test of cure for Helicobacter pylori by urea breath test at least four weeks after antibiotics and two weeks after stopping omeprazole | completed | GL-ACG-HP-2024 | S |
| Knee osteoarthritis: walking and strengthening exercise, acetaminophen as needed, no nonsteroidal anti-inflammatory drugs after her ulcer | completed | GL-ACR-OA-2019 | S |
| Germline multigene panel testing with genetic counseling before surgery, as recommended for breast cancer diagnosed at 65 or younger | completed | GL-ASCO-SSO-GERM-2024, GL-NCCN-BREAST-2025 | S |
| Left breast-conserving surgery (lumpectomy) with sentinel lymph node biopsy, her choice after mastectomy was also explained; no axillary dissection if one or two sentinel nodes are involved and she has whole-breast radiation | completed | GL-NCCN-BREAST-2025, GL-ASCO-AXILLA-2021 | S |
| Hypofractionated whole-breast and regional nodal radiation with a tumor-bed boost by the radiation oncology team, booked in the afternoons so she can write in the mornings | completed | GL-NCCN-BREAST-2025 | S |
| Letrozole 2.5 mg daily for at least five years with ribociclib 400 mg on days 1 to 21 of each 28-day cycle for three years, chosen by her; no chemotherapy with a recurrence score of 17; ECG before starting and about day 14, blood counts and liver tests every two weeks for two cycles and then at the start of the next four cycles, and electrolytes at the start of the first six cycles; avoid drugs that prolong the QT interval | completed | GL-NCCN-BREAST-2025, GL-ASCO-CDK46-2024, GL-FDA-RIBOCICLIB-2026, GL-ASCO-ENDO-2019 | S |
| Bone health: baseline DXA, dental check, then zoledronic acid 4 mg every six months for three years; vitamin D and calcium from food; weight-bearing exercise; DXA every two years | completed | GL-ASCO-BMA-2022, GL-CMID-2026 | S |
| Survivorship care: history and examination every 3 to 6 months, a mammogram 6 to 12 months after radiation and then yearly, no routine tumor markers or body imaging; lymphedema checks, joint-pain and hot-flash review, distress screening, and a written survivorship care plan | completed | GL-CMID-2026, GL-ACS-ASCO-SURV-2016, GL-ASCO-FU-2013 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Receive the biopsy result in person within ten days, explained in plain words, with a copy of the report | 2026-03-18 | completed | Told the diagnosis in person nine days after presentation, with the pathology report in hand; teach-back confirmed her understanding | S |
| Make each treatment decision herself after hearing the options, benefits, and harms | 2026-04-20 | completed | Chose breast-conserving surgery and, after the pathology, radiation, letrozole, ribociclib, and zoledronic acid | S |
| Complete surgery and radiation, then start endocrine therapy, within four months of diagnosis | 2026-06-15 | completed | Lumpectomy at three weeks, radiation completed at ten weeks, letrozole and ribociclib started at thirteen weeks | S |
| Take adjuvant systemic therapy safely, with every safety check the drugs require done on schedule | 2026-12-07 | active | Ribociclib started with QTcF 418 ms; blood counts and liver tests on schedule; the day-14 ECG was late, as recorded | S |
| Keep writing at least four mornings a week through treatment | 2026-12-07 | active | Writing most mornings, with radiation booked in the afternoons | S |